Search results
Showing 2056 to 2070 of 8929 results
In development Reference number: GID-TA10326 Expected publication date: TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
In development Reference number: GID-TA10497 Expected publication date: TBC
In development Reference number: GID-TA10542 Expected publication date: TBC
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Awaiting development Reference number: GID-TA10553 Expected publication date: TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development Reference number: GID-TA10573 Expected publication date: TBC
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Awaiting development Reference number: GID-TA10604 Expected publication date: TBC
Awaiting development Reference number: GID-TA10605 Expected publication date: TBC
In development Reference number: GID-TA10248 Expected publication date: TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
In development Reference number: GID-TA10249 Expected publication date: TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
In development Reference number: GID-TA10250 Expected publication date: TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
In development Reference number: GID-TA10251 Expected publication date: TBC
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]
Awaiting development Reference number: GID-TA10279 Expected publication date: TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Awaiting development Reference number: GID-TA10431 Expected publication date: TBC
Awaiting development Reference number: GID-TA10439 Expected publication date: TBC
In development Reference number: GID-TA10446 Expected publication date: TBC